Pacylex Pharmaceuticals: Pioneering a Path to Promising Cancer Therapies

Pacylex Pharmaceuticals stands out as a beacon of innovation, poised to revolutionize cancer treatment options. It is pioneering an entirely new class of cancer fighting compounds, NMT inhibitors.  Zelenirstat is the  first NMT inhibitor drug tested in patients. It is taken orally once per day. This clinical stage company is not merely developing a drug; it's creating a new category  in cancer treatment.

Zelenirstat, an oral investigational therapy inhibiting myristoylation in cancer and autoimmune disorders has demonstrated remarkable potential in Phase 1 studies. A Phase 2 dose was determined and so far, patients receiving that dose generally survived longer while their tumours were kept in check.

What sets Zelenirstat apart is its unique mechanism of action. By targeting membrane-associated proteins at the core of cancer signalling in leukemia and lymphoma, it disrupts the cascade before it can spread to redundant pathways. It also disrupts the formation of blood vessels that feed solid tumours. These approaches position Zelenirstat as a potent alternative to traditional chemotherapies and immunotherapies.

In the face of dismal survival rates for cancers like lung cancer and acute myeloid leukemia, Pacylex's lead drug shows promise in eliminating tumours in animal cancer models. With the Phase 1 clinical trial boasting excellent bioavailability, a favourable safety profile, and drug exposure sufficient to kill cancer cells in vitro, Pacylex has begun a Phase 2 study in lymphoma (DLBCL), and is ready to start a similar study in solid tumour patients and leukemia (AML) aiming for an initial accelerated approval in AML by 2026.

As Pacylex Pharmaceuticals seeks Series B investors, their mission to bring Zelenirstat to the forefront of cancer care is not just ambitious; it's a beacon of hope for countless patients and a testament to the relentless pursuit of a cure. The company's strides towards bridging the gap between scientific innovation and clinical application mark them as a key player in the future landscape of cancer therapeutics.